OLYMPUS True to Life








Olympus Corporation


Company Presentation

April 2024

Disclaimer:

- Any content or information ("Content") presented herein is illustrative in nature and does not guarantee or represent specific information, outcomes or results.
- Under no circumstances shall Olympus or its employees, consultants, agents or representatives be liable for any costs, expenses, losses, claims, liabilities, or other damages (whether direct, indirect, special, incidental, consequential, or otherwise) that may arise from, or be incurred in connection with, the Content or any use thereof.










Corporate Philosophy

OUR PURPOSE Making people's lives healthier, safer and more fulfilling


OUR CORE VALUES




Our Contribution to Patients Care



Our Contribution to Patients Care



Making people's lives healthier, safer and more fulfilling



32,805

Employees Worldwide*

* As of March 2023, Including discontinued operation 4,124

38

Countries or Regions*

* As of March 2023

Making people's lives healthier, safer and more fulfilling



TOP 100

Global Innovator

Olympus has been awarded as one of the top 100 most innovative companies in the world.

https://clarivate.com/top-100-innovators/

Awards

Since 2012 to 2020, and in 2022 and 2023, Since 1966, Olympus has been consistently honored with national and international design awards for its innovative product designs*

*As of March 2023



14,000

Patents

across our product portfolio*

*As of March 2023



Emissions by 2030

We set as a target of achieving net zero CO2 emissions by 2030 from our site operations

*As of March 2023





Revenue by Business Divisions

¥11.9 bn 1.3%

Other


¥881.9 bn March 2023 ¥551.8 bn 62.6%

Endoscopic Solutions


Therapeutic Solutions

Revenue by Region






Page 14



Revenue and Operating Profit



Note) We split off the imaging business to a special purpose company established by Japan Industrial Partners, Inc. on January 1, 202 In this regard, imaging division is categorized as a discontinued operation, effective Q2 of FY2021 and figures of FY2020 is restated. *Due to rounding, the total may not add up to 100%

Endoscopic Solutions

Gastrointestinal Endoscopy System


Surgical Endoscopy System

Reprocessing

Customer Solutions (Digital Healthcare Solutions) Services

Medical







4K surgical endoscopy system



3D surgical endoscopy system



Endoscope reprocessor



Customer Solutions Virtual Collaboration



Repair center

Note: Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.

Therapeutic Solutions

Endotherapy Devices

Urology







Note: Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.

Page 17



TFL lithotripsy fibers









iTind ™ System1







PLASMA+TM resection generator and PLASMA+ consumables

Respiratory

1 iTind procedure does not require a permanent implant and preserves sexual function and continence, while reducing the need for a post procedure catheter. Procedure can be done in the MD office setting.



Bronchoscopy (traditional and single-use) and endoscopic devices









Endobronchial valves4

- 2 EBUS:Endobronchial ultrasound
- 3 EBUS-TBNA: Endobronchial ultrasound-guided transbronchial needle aspirations
- 4 The device is approved as Humanitarian Device Exemption. Authorized by Federal law for use in the treatment of air leaks. The effectiveness of this device for this use has not been demonstrated.

Surgical Energy Devices



Ear, Nose and Throat

Rhino-laryngo scope

Gynecology

Rigid endoscope (Telescope)



Guiding Principles

Patient safety and sustainability



- Resolve pending commitments to the FDA, build a foundation of trust through measurable actions and data with regulatory bodies and with our customers.
- 2 Lead in organization health and ESG

Innovation for growth



- 3 Strengthen the Olympus® brand; elevate the experience of our customers
- Grow our business through purposeful innovation and acquisitions

Productivity



- 5 Build a high performing organization focused on patient safety and product quality
- Support simplicity and operational efficiency



Four Value Pools



Business and Global Expansion

- Increased demand for endoscopic procedures for diseases in our focus areas of GI, urology, and respiratory due to the increase in cancer and chronic diseases
- Regional expansion of the EVIS X1™ endoscopy system as our growth driver
- Sustainable growth opportunities in China



Care Pathway Enhancement

 Enhancing patient care pathways in key areas such as early detection, characterization/diagnosis/staging, and treatment to meet everchanging expectations for patient care



Strategic M&A

Focus on tuck-in M&A* in core or highgrowth adjacencies


* M&As that fit our portfolio and complement or enhance our existing business



Intelligent Endoscopy Ecosystem Shaping a new era of Intelligent, Al-powered endoscopy

For a Sustainable Growth


We will continue to Focus on disease states where Olympus can have an impact as an industry-leader and Shape and Enable future growth by investing in new ways to elevate the standard of care.



Activities to enable investments and innovation



- Execute transformation with the aim of a single global quality system and fully harmonize processes
- Enhance Global Quality and Compliance functions to support consistent execution
- Resolve compliance issues and complete remediation



R&D – investments to accelerate innovation

- Apply an unmet need-oriented innovation approach
- Invest for future by furthering an innovation engine
- Pro-actively seek out strategic partnerships
- Work to accelerate time-tomarket



Mfg & SCM – opportunity for COGS improvements

- Improve efficiency and cost to apply a fit-for-purpose organization and processes
- Actions include site and resource streamlining, fast-track efficiencies, procurement and supply chain best-practices, and uncover benefits from digitization



- Further fine-tune our global governance and operation to establish a high-performing organization of a global medical company that unlocks capital to drive innovation
- Enable cross-functional and effective decision-making, with efficient resource allocation and rigorous execution to fund & deliver key projects


*TOM = target operating model

Support patient safety according to the highest industry standards



FY24-26 Financials

Competitive growth along with steady value creation



^{*}constant currency basis **Adjusted for extraordinary Items

⁻ Exclude "Other income / expenses" - No adjustment will be made for the impact of exchange rate fluctuations; actual exchange rate will be used



Common Topics in ESG*







^{*}Major examples only / not limited

ESG six focus areas and materiality topics with top priorities



Contribution to health

equity and access







Quality and safety in product, service and solution



Supply Chain

Supply chain risk mitigation and resilience



Healthy **Organization**

Diversity, equity and inclusion




Society and Circular **Economy**

Circularity through product stewardship, carbon emissions (Scope 1, 2 and 3)



Healthcare Access and Outcome







* CRC: Colorectal cancer



Compliance, Product Quality and Safety





Quality and safety in product, service and solution

Timely ESG disclosures

According to SASB Standards





Responsible Supply Chain







Healthy Organization





30%

Promoting the Advancement of Women

Management positions held by women

by FY28 globally

100%

Paternity Leave

Eligible male employees in Japan take parental leave by

by FY26



Carbon Neutral Society and Circular Economy







Net-zero

Carbon Neutral

Net-zero GHG emissions across scope 1, 2 and 3* by 2040

In our site operations across scope 1 and 2* by 2030



Scope 1: Direct greenhouse gas emissions by combustion of fuels in our sites

Scope 2: Indirect greenhouse gas emissions from our sites use of electricity, heat or steam supplied by other companies


Scope 3: Other indirect greenhouse gas emissions (excluding Scope 1 and Scope 2)

Corporate Governance









An Evolution in Corporate Culture

A Healthy Organization

Committed to delivering Olympus' Purpose by creating a working culture where everyone is empowered to perform their best

Purpose-driven



Inspirational Leadership

Leaders present clear strategies and guide Olympus' future

Collaboration

Collaboration across company departments and geographical regions, and realization of open and constructive discussions

External. Customer Orientation

3

Identify customer and market trends and respond to future business needs by valuing new ideas

Empowerment Anyone making

decisions is recognized as bearing responsibility and charts their own career path

People-centric



Encouraged to Challenge

Fostering a culture that values diverse ideas, and encourages taking on new challenges

Work-life **Balance**

Creating attractive work environments and valuing employee wellbeing

6

Our Core Values (Guidelines for Day-to-Day Activities)

The six dimensions necessary to achieve a Healthy Organization and Our Core Values

Healthy Organization

We define our aim for a Healthy Organization as "Committed to delivering Olympus' Purpose by creating a working culture where everyone is empowered to perform their best" and we consider there to be six dimensions which is necessary to bring it to fruition. We are currently advancing initiatives at the global level to further improve those six dimensions.



Helpful Tools and Practices to Support Our Journey

A Healthy Organization Committed to delivering Olympus' Purpose by creating a working culture where everyone is empowered to perform their best **Purpose-driven People-centric** Inspirational Collaboration **Empowerment Encouraged to** Work-life External. Leadership Customer Challenge **Balance** Orientation **Olympus** Meeting Micro habits **Exchange** norms 6 **On-boarding** Team build Community 1 on 1 building 5-minute feedback Our Core Values (Guidelines for Day-to-Day Activities) The six dimensions necessary to achieve Key issues

a Healthy Organization and Our Core Values

addressed


	ealth nitiatives	Description
	lympus kchange	Cross-functional exchange of knowledge; improves understanding in areas out of own organization, and Olympus' business etc.
2 0	nboarding	Content enables new joiners for better cross collaboration, and content enables first experience in global projects or environment
	ommunity uilding	Enable colleagues to develop communities to increase cross-collaboration & networking
4 er	icro-habits to ncourage nallenge	Encourages failure learning mindset through adopting micro-habits and sharing best practices
5 M	eeting norms	Approach and tools intended to improve meeting efficiency and decrease unnecessary meetings
6 Te	eam Build	Approach involves learning and reflection to improve understanding and create a comfortable environment within team
7 1	on 1	Support for managers and members to regularly interact, support growth of members and raise performance as result
\mathbf{x}	minute edback	A short and timely casual session to encourage two-way feedback

Note: Some other initiatives are ongoing in parallel.

Core Values Survey

The Olympus Core Values Survey represents an important employee engagement tool that supports our aim to create a Healthy Organization.

And we conduct employee pulse check every year and aimed to track the impact and progress of the actions we derived from last year's Global Core Values Survey (GCVS), to check if we are right on track to further improve enablement, engagement, and to support retention of our employees.



As of Nov. 2022



Follow-up Measures for Our Core Values Survey



Gemba Visit

Management visit Factory and R&D to close the gap between management and staff. Management members gain insight into the current situation that is useful for making decisions and a collaborator in leading the company.

6,000*

Global Program

We are providing training to all employees worldwide to strengthen their business and execution since we believe this is a key factor for ensuring organizational change.

No. of participants*

4,300*

Global Communication Skill Strengthening Program

In Japan, we are undertaking the Global Communication Skill Strengthening Program to improve English proficiency and support cross-cultural understanding.

No. of participants*

*2020-2022 As of Nov 2022





Company Outline

Company Name

Olympus Corporation

Market

Tokyo Stock Exchange, Prime Market (7733)

Established

October 12, 1919

Director,
Representative Executive Officer,
President and CEO

Stefan Kaufmann

Head Office

2951 Ishikawa-machi, Hachioji-shi, Tokyo 192-8507, Japan

Share Capital

124.643 billion yen (As of March 31, 2023)

Consolidated Revenue

881.9 billion yen (Fiscal year ended March 31, 2023)

Consolidated Headcount

32,805 (As of March 31, 2023, Including discontinued operation 4,124)



Executive Officers



Director, Representative Executive Officer, Executive Chairperson and ESG Officer



Director, Representative
Executive Officer, President and
Chief Executive Officer

Stefan Kaufmann



Executive Officer and Endoscopic Solutions
Division Head

Frank Drewalowski



Executive Officer and Therapeutic Solutions Division Head



Executive Officer and Chief Financial Officer



Gabriela Kaynor

Executive Officer and
Chief Strategy Officer



Tetsuo Kobayashi

Executive Officer and Chief Manufacturing and Supply Officer



André Roggan

Executive Officer and Chief Technology Officer



Executive Officer and Chief Quality Officer




vecutive Officer and Chie


Executive Officer and Chief Human Resources Officer


Olympus Locations











Launch of BX series of biological microscopes and UIS series of object lenses, which improved product appeal in the AX, BX, CX, and IX series of microscopes.

Launch of C-800L/D-300L and C-400L/D-200L. Olympus' first consumer digital cameras.

Launch of MX50 semiconductor inspection microscope.

Introduction of **IPLEX**™ industrial videoscope system.

2001



1993



1996



1996





1995

Establishment of Olympus Endo-Repair Europa GmbH, endoscope repair service center for the European market, in Hamburg, Germany.

1996

Launch of **FLUOVIEW**™ confocal laser scanning biological microscope.




2000


Introduction of **EVIS EXERA™** series endoscopic video system.




2002


Launch of VISERA™ series, an integrated video system for surgery.







Page 50



OLYMPUS

